Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $44.85 down -2.84% from its previous closing price of $46.16. In other words, the price has decreased by -$2.84 from its previous closing price. On the day, 0.86 million shares were traded. PTGX stock price reached its highest trading level at $46.01 during the session, while it also had its lowest trading level at $44.28.
Ratios:
For a deeper understanding of Protagonist Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.06. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 22 ’25 when Ali Asif sold 1,756 shares for $46.00 per share. The transaction valued at 80,776 led to the insider holds 61,065 shares of the business.
Waddill William D. sold 4,000 shares of PTGX for $217,000 on Mar 17 ’25. The Director now owns 13,130 shares after completing the transaction at $54.25 per share. On Mar 17 ’25, another insider, WILLIAM D WADDILL, who serves as the Director of the company, bought 4,000 shares for $54.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 2753085696 and an Enterprise Value of 2345038336. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 10.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.34 while its Price-to-Book (P/B) ratio in mrq is 4.05. Its current Enterprise Value per Revenue stands at 5.398 whereas that against EBITDA is 9.244.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.62, which has changed by 0.78330016 over the last 52 weeks, in comparison to a change of 0.07545352 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.60, while it has fallen to a 52-week low of $24.22. The 50-Day Moving Average of the stock is -0.63%, while the 200-Day Moving Average is calculated to be 5.76%.
Shares Statistics:
For the past three months, PTGX has traded an average of 1.18M shares per day and 1219420 over the past ten days. A total of 61.04M shares are outstanding, with a floating share count of 57.88M. Insiders hold about 5.71% of the company’s shares, while institutions hold 100.05% stake in the company. Shares short for PTGX as of 1743379200 were 4706298 with a Short Ratio of 4.00, compared to 1740700800 on 4865114. Therefore, it implies a Short% of Shares Outstanding of 4706298 and a Short% of Float of 7.7700000000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
